Comparing neurostimulation technologies in refractory focal-onset epilepsy

Area of Science:

• Neurology
• Neurosurgery
• Medical Devices

Background:

• Pharmacoresistant focal epilepsy presents limited treatment options after surgical failure.
• Neurostimulation offers an alternative therapeutic strategy for refractory epilepsy.

Purpose of the Study:

• To introduce Vagal Nerve Stimulation (VNS), Deep Brain Stimulation (DBS), and Cortical Responsive Stimulation (CRS) to a non-specialist audience.
• To compare the long-term (5-year) efficacy and safety of VNS, DBS, and CRS for refractory focal epilepsy.

Main Methods:

• Literature review of studies reporting long-term efficacy (>5 years) of VNS, CRS, and DBS in refractory focal/partial epilepsy.
• Searches conducted in PubMed and Cochrane databases.
• Outcomes compared included responder rate, seizure frequency reduction, seizure freedom, adverse events, neuropsychological outcomes, and quality of life.

Main Results:

• All neurostimulation technologies demonstrated long-term efficacy with improved seizure control over time.
• Sustained improvements in quality of life were observed across all modalities.
• Intracranial neurostimulation (DBS, CRS) had a higher side effect profile than extracranial stimulation (VNS), but all were deemed safe.

Conclusions:

• Neurostimulation therapies (VNS, DBS, CRS) are effective long-term options for pharmacoresistant focal epilepsy.
• A pragmatic decision tree was developed to guide patient management based on synthesized findings.
• While direct comparisons are challenging due to methodological differences, all modalities show promise.